📊 ALLO Key Takeaways
Is Allogene Therapeutics, Inc. (ALLO) a Good Investment?
Allogene is a pre-commercial stage biopharmaceutical company with zero revenue and severe cash burn of $149.2M annually, indicating it is not yet generating product sales. While the company maintains a strong liquidity position with a 7.93x current ratio and $51.7M in cash, at the current burn rate this runway extends only to mid-2026, creating significant going concern risk without successful clinical advancement or financing.
Allogene Therapeutics shows a weak fundamental profile: revenue fell to zero, losses remain very large, and free cash flow is deeply negative, indicating the business is still far from self-sustaining. While the balance sheet has no long-term debt and strong headline liquidity ratios, the current cash balance appears thin relative to annual operating cash burn, increasing dependence on future financing.
Why Buy Allogene Therapeutics, Inc. Stock? ALLO Key Strengths
- Excellent liquidity position with 7.93x current ratio and $51.7M cash on hand
- No long-term debt obligations reducing financial leverage risk
- Reasonable balance sheet with total assets of $415.9M and modest liabilities of $123.4M
- Positive EPS trend with 34.1% YoY improvement despite continued losses
- Debt-free balance sheet reduces solvency risk from leverage
- High current and quick ratios indicate strong near-term balance sheet liquidity on paper
- Equity base of $292.54M provides some balance sheet cushion despite ongoing losses
ALLO Stock Risks: Allogene Therapeutics, Inc. Investment Risks
- Zero revenue generation with 100% YoY decline indicates no commercial products yet approved
- Massive operating cash burn of $149.2M annually with only ~4 months of cash runway remaining
- Negative net income of -$190.9M and negative ROE of -65.3%, ROA of -45.9% showing significant shareholder value destruction
- High risk of dilutive financing or failed clinical trials given current burn rate and pre-commercial status
- 12 Form 4 insider filings in last 90 days warrant investigation for potential negative signals
- Zero revenue and persistent net losses signal no proven commercial engine
- Operating cash outflow of $149.25M materially exceeds cash and equivalents of $51.69M, implying funding pressure
- Negative ROE and ROA reflect poor capital efficiency and weak growth quality
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway projections
- Clinical trial progress and regulatory milestone announcements for lead programs
- Timing and results of any financing activities or capital raises
- Product revenue recognition timeline if any programs achieve approval
- Quarterly cash burn versus cash and equivalents
- Any return of product revenue or meaningful improvement in operating loss
Allogene Therapeutics, Inc. (ALLO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.93x current ratio provides a solid financial cushion.
ALLO Profit Margin, ROE & Profitability Analysis
ALLO vs Healthcare Sector: How Allogene Therapeutics, Inc. Compares
How Allogene Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allogene Therapeutics, Inc. Stock Overvalued? ALLO Valuation Analysis 2026
Based on fundamental analysis, Allogene Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allogene Therapeutics, Inc. Balance Sheet: ALLO Debt, Cash & Liquidity
ALLO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allogene Therapeutics, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
ALLO Revenue Growth, EPS Growth & YoY Performance
ALLO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$41.4M | $-0.19 |
| Q2 2025 | N/A | -$50.9M | $-0.23 |
| Q1 2025 | N/A | -$59.7M | $-0.28 |
| Q3 2024 | N/A | -$62.3M | $-0.32 |
| Q2 2024 | N/A | -$65.0M | $-0.35 |
| Q1 2024 | $22.0K | -$65.0M | $-0.38 |
| Q3 2023 | $43.0K | -$61.3M | $-0.37 |
| Q2 2023 | $44.0K | -$74.8M | $-0.52 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Allogene Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALLO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allogene Therapeutics, Inc. (CIK: 0001737287)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALLO
What is the AI rating for ALLO?
Allogene Therapeutics, Inc. (ALLO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALLO's key strengths?
Claude: Excellent liquidity position with 7.93x current ratio and $51.7M cash on hand. No long-term debt obligations reducing financial leverage risk. ChatGPT: Debt-free balance sheet reduces solvency risk from leverage. High current and quick ratios indicate strong near-term balance sheet liquidity on paper.
What are the risks of investing in ALLO?
Claude: Zero revenue generation with 100% YoY decline indicates no commercial products yet approved. Massive operating cash burn of $149.2M annually with only ~4 months of cash runway remaining. ChatGPT: Zero revenue and persistent net losses signal no proven commercial engine. Operating cash outflow of $149.25M materially exceeds cash and equivalents of $51.69M, implying funding pressure.
What is ALLO's revenue and growth?
Allogene Therapeutics, Inc. reported revenue of $0.0.
Does ALLO pay dividends?
Allogene Therapeutics, Inc. does not currently pay dividends.
Where can I find ALLO SEC filings?
Official SEC filings for Allogene Therapeutics, Inc. (CIK: 0001737287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALLO's EPS?
Allogene Therapeutics, Inc. has a diluted EPS of $-0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALLO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Allogene Therapeutics, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALLO stock overvalued or undervalued?
Valuation metrics for ALLO: ROE of -65.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALLO stock in 2026?
Our dual AI analysis gives Allogene Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALLO's free cash flow?
Allogene Therapeutics, Inc.'s operating cash flow is $-149.2M, with capital expenditures of $386.0K.
How does ALLO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -65.3% (avg: 15%), current ratio 7.93 (avg: 2).